Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia
Moffitt Cancer Center researchers, in collaboration with the Lung Cancer Mutation Consortium, have developed a process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients. Adenocarcinoma is the most common type of lung cancer in the United States with approximately 130,000 people diagnosed each year.
The study, published in the May 21 issue of The Journal of the American Medical Association, investigated 10 highly mutated and altered genes that contribute to cancer progression, termed oncogenic driver genes, in more than 1,000 lung cancer patients. Patients with adenocarcinoma have a high probability of having mutated oncogenic driver genes in their tumors.
As new oncogenic driver genes are identified, the testing process becomes less efficient because more genes need to be analyzed in limited amounts of tumor tissue. The researchers developed a process to analyze multiple genes at one time with small amounts of patient tissue. They found that 64 percent of lung adenocarcinoma patients had at least one oncogenic driver gene.
Patients who had mutations were offered therapies targeted to their specific mutation. The researchers found that those patients who had targeted treatment against an oncogenic driver gene survived longer than those patients who did not.
"Precision medicine is the future of cancer care. We are continuing this study by attempting to profile all advanced lung adenocarcinoma patients for driver genes to match them with appropriate therapies," explained Eric B. Haura, M.D., director of Moffitt's Lung Cancer Center of Excellence. "We'd like to extend this further to examine for driver genes in other types of lung cancer, such as squamous cell lung cancer."
The researchers also plan to use this technology to study drug resistance and are developing additional platforms to guide decision making in the clinic.
Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment. This study is the first of its kind that supports the concept that the simultaneous analysis of genetic mutations is possible with the goal of delivering more personalized medicine.
Explore further: Genomic tumor testing to match lung cancer patients with targeted drugs transforms care
More information: http://ift.tt/1oXq5h2
Medical Xpress on facebook
Related Stories
Genomic tumor testing to match lung cancer patients with targeted drugs transforms care
May 20, 2014
New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
Trial confirms promise of stratified lung cancer treatment
May 22, 2014
(Medical Xpress)—Routine tests that look for multiple, specific genetic changes in patients' lung tumours could help doctors select targeted treatments, a US study has confirmed.
ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
May 31, 2014
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small ...
Recurrent but rare mutations might underlie cancer growth
Feb 26, 2014
A potential new gene mutation that might drive lung cancer development and growth has been identified by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard ...
Research shows molecular, protein targeting therapies may be best treatment for certain lung cancer
Jan 07, 2014
University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most ...
Recommended for you
Novel NextGen sequencing test developed for retinoblastoma
2 hours ago
Researchers at Children's Hospital Los Angeles (CHLA) have developed a unique next-generation sequencing test for the gene linked to retinoblastoma. The new approach is both more comprehensive and can be ...
Stopping the spread of breast cancer
2 hours ago
The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine® scientists have discovered a new pathway that can stop breast cancer cells from ...
Liver cancer vaccine effective in mice
3 hours ago
Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.
Tracer could indicate radiation benefit to patient
3 hours ago
A world-first radiotherapy treatment trial by University of WA researchers could have a major impact on the quality of life for mesothelioma patients.
Prostate cancer testing is on trial
3 hours ago
(Medical Xpress)—The University of Sydney's School of Public Health is seeking people to participate in a "community jury" to independently asses the process of Prostate Specific Antigen (PSA) testing in ...
Researchers use new simple cost effective technology to unravel cancer through standard imaging
3 hours ago
Researchers at Maastricht University Medical Center+ (Maastricht UMC+) and the MAASTRO Clinic have developed a new medical imaging analysis method to predict the risk of dying of cancer in patients. For the first time, they ...
User comments
© Medical Xpress 2011-2014, Science X network
Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia
Moffitt Cancer Center researchers, in collaboration with the Lung Cancer Mutation Consortium, have developed a process to analyze mutated genes in lung adenocarcinoma to help better select personalized treatment options for patients. Adenocarcinoma is the most common type of lung cancer in the United States with approximately 130,000 people diagnosed each year.
The study, published in the May 21 issue of The Journal of the American Medical Association, investigated 10 highly mutated and altered genes that contribute to cancer progression, termed oncogenic driver genes, in more than 1,000 lung cancer patients. Patients with adenocarcinoma have a high probability of having mutated oncogenic driver genes in their tumors.
As new oncogenic driver genes are identified, the testing process becomes less efficient because more genes need to be analyzed in limited amounts of tumor tissue. The researchers developed a process to analyze multiple genes at one time with small amounts of patient tissue. They found that 64 percent of lung adenocarcinoma patients had at least one oncogenic driver gene.
Patients who had mutations were offered therapies targeted to their specific mutation. The researchers found that those patients who had targeted treatment against an oncogenic driver gene survived longer than those patients who did not.
"Precision medicine is the future of cancer care. We are continuing this study by attempting to profile all advanced lung adenocarcinoma patients for driver genes to match them with appropriate therapies," explained Eric B. Haura, M.D., director of Moffitt's Lung Cancer Center of Excellence. "We'd like to extend this further to examine for driver genes in other types of lung cancer, such as squamous cell lung cancer."
The researchers also plan to use this technology to study drug resistance and are developing additional platforms to guide decision making in the clinic.
Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment. This study is the first of its kind that supports the concept that the simultaneous analysis of genetic mutations is possible with the goal of delivering more personalized medicine.
Explore further: Genomic tumor testing to match lung cancer patients with targeted drugs transforms care
More information: http://ift.tt/1oXq5h2
Medical Xpress on facebook
Related Stories
Genomic tumor testing to match lung cancer patients with targeted drugs transforms care
May 20, 2014
New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
Trial confirms promise of stratified lung cancer treatment
May 22, 2014
(Medical Xpress)—Routine tests that look for multiple, specific genetic changes in patients' lung tumours could help doctors select targeted treatments, a US study has confirmed.
ALK, ROS1 and now NTRK1: Study shows prevalence of new genetic driver in lung cancer
May 31, 2014
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small ...
Recurrent but rare mutations might underlie cancer growth
Feb 26, 2014
A potential new gene mutation that might drive lung cancer development and growth has been identified by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard ...
Research shows molecular, protein targeting therapies may be best treatment for certain lung cancer
Jan 07, 2014
University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most ...
Recommended for you
Novel NextGen sequencing test developed for retinoblastoma
2 hours ago
Researchers at Children's Hospital Los Angeles (CHLA) have developed a unique next-generation sequencing test for the gene linked to retinoblastoma. The new approach is both more comprehensive and can be ...
Stopping the spread of breast cancer
2 hours ago
The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine® scientists have discovered a new pathway that can stop breast cancer cells from ...
Liver cancer vaccine effective in mice
3 hours ago
Tweaking a protein expressed by most liver cancer cells has enabled scientists to make a vaccine that is exceedingly effective at preventing the disease in mice.
Tracer could indicate radiation benefit to patient
3 hours ago
A world-first radiotherapy treatment trial by University of WA researchers could have a major impact on the quality of life for mesothelioma patients.
Prostate cancer testing is on trial
3 hours ago
(Medical Xpress)—The University of Sydney's School of Public Health is seeking people to participate in a "community jury" to independently asses the process of Prostate Specific Antigen (PSA) testing in ...
Researchers use new simple cost effective technology to unravel cancer through standard imaging
3 hours ago
Researchers at Maastricht University Medical Center+ (Maastricht UMC+) and the MAASTRO Clinic have developed a new medical imaging analysis method to predict the risk of dying of cancer in patients. For the first time, they ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment